Protalix (PLX) Price & Analysis

Compare

849 Followers

PLX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.82 - $3.10

Previous CloseN/A

Volume368.29K

Average Volume (3M)1.03M

Market Cap

$116.23M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)35.5

Beta0.64

Next Earnings

Aug 18, 2025

EPS Estimate

0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding79,607,120

10 Day Avg. Volume563,176

30 Day Avg. Volume1,034,504

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$15.00

Price Target Upside906.71% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Commercial ApprovalElfabrio remains favorable with commercial approval across 23 territories globally for the treatment of Fabry disease.

Financial HealthThe company has $34.7M in cash and short-term bank deposits, expected to be sufficient to fund operations to cash flow breakeven.

Bears Say

Revenue PerformanceProtalix reported 1Q25 revenues from selling goods of $10M vs. forecast of $21.6M, attributed to choppiness in royalty-based revenue.

Royalty-Based RevenueProtalix reported 1Q25 revenues from selling goods of $10M vs. forecast of $21.6M, attributed to choppiness in royalty-based revenue.

Protalix News

Protalix appoints Gilad Mamlok as CFO

Protalix (PLX) announced the appointment of Gilad Mamlok to serve as the company’s new senior VP and CFO,...

11d ago

PLX

Protalix Appoints New CFO to Boost Growth Strategy

Protalix ( ($PLX) ) has provided an update. On July 21, 2025, Protalix BioTherapeutics announced the appointment of...

11d ago

PLX

Protalix added to Russell 3000, Russell 2000 Indexes

Protalix (PLX) announced the company has been added to the Russell 3000 and Russell 2000 Indexes, effective as...

1M ago

PLX

Protalix Holds Annual Stockholders Meeting in Tel Aviv

An announcement from Protalix ( ($PLX) ) is now available. On June 26, 2025, Protalix Biotherapeutics, Inc. held...

1M ago

PLX

Protalix’s Growth Potential: Buy Rating Backed by Elfabrio’s Market Expansion and Promising PRX-115 Development

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Protalix (PLX – Research Report). The...

2M ago

PLX

Protalix BioTherapeutics Reports Strong Q1 2025 Growth

Protalix Biotherapeutics ( ($PLX) ) has released its Q1 earnings. Here is a breakdown of the information Protalix...

3M ago

PLX

Protalix BioTherapeutics Earnings Call: Growth Amid Challenges

Protalix Biotherapeutics (($PLX)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

PLX

PLX Upcoming Earnings Report: What to Expect?

Protalix Biotherapeutics (PLX) is scheduled to report 1st quarter earnings on 05/09/2025, before the market opens. Regarding Q1...

3M ago

PLX

Protalix files $100M mixed securities shelf

17:01 EDT Protalix (PLX) files $100M mixed securities shelf Published first on TheFly – the ultimate source for...

3M ago

PLX

Protalix’s Strong Financial Performance and Promising Product Outlook Justify Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Protalix (PLX – Research Report). The...

3M ago

PLX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

DDC

PLX

Protalix CFO Eyal Rubin Announces Resignation

An update from Protalix ( ($PLX) ) is now available. On April 21, 2025, Eyal Rubin, the Senior...

3M ago

PLX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

PLX

SLS

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge

Protalix Biotherapeutics ($PLX) has gained investor’s attention, and reported a record revenue increase in its fiscal year 2024,...

4M ago

PLX

PLX FAQ

What was Protalix Biotherapeutics’s price range in the past 12 months?

Protalix Biotherapeutics lowest stock price was $0.82 and its highest was $3.10 in the past 12 months.

What is Protalix Biotherapeutics’s market cap?

Protalix Biotherapeutics’s market cap is $116.23M.

When is Protalix Biotherapeutics’s upcoming earnings report date?

Protalix Biotherapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 17 days.

How were Protalix Biotherapeutics’s earnings last quarter?

Protalix Biotherapeutics released its earnings results on May 09, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0.08 by -$0.13.

Is Protalix Biotherapeutics overvalued?

According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protalix Biotherapeutics pay dividends?

Protalix Biotherapeutics does not currently pay dividends.

What is Protalix Biotherapeutics’s EPS estimate?

Protalix Biotherapeutics’s EPS estimate is 0.04.

How many shares outstanding does Protalix Biotherapeutics have?

Protalix Biotherapeutics has 79,607,120 shares outstanding.

What happened to Protalix Biotherapeutics’s price movement after its last earnings report?

Protalix Biotherapeutics reported an EPS of -$0.05 in its last earnings report, missing expectations of $0.08. Following the earnings report the stock price went down -40.484%.

Which hedge fund is a major shareholder of Protalix Biotherapeutics?

Currently, no hedge funds are holding shares in PLX

Protalix Stock Smart Score

Neutral

Fundamentals

Return on Equity

10.42%

Trailing 12-Months

Asset Growth

-17.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protalix Biotherapeutics

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that specializes in the development and commercialization of recombinant therapeutic proteins using its proprietary plant cell-based protein expression system, ProCellEx. The company operates primarily in the healthcare and biotechnology sectors, focusing on the production of therapeutic proteins for the treatment of various diseases, including rare and orphan diseases.

Protalix (PLX) Earnings & Revenues

PLX Earnings Data >

PLX Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mix of positive and negative aspects. The company showcased substantial revenue growth, promising developments in its pipeline, and a strong cash position. However, these were counterbalanced by increased costs associated with goods sold and R&D, alongside a continued net loss. The sentiment of the call is balanced.Read More>

PLX Stock 12 Month Forecast

Average Price Target

$15.00

▲(906.71%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2020","6":"May<br/>2021","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.48,2.52,3.56,4.6,5.640000000000001,6.68,7.720000000000001,8.76,9.8,10.84,11.88,12.920000000000002,13.96,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.48,2.52,3.56,4.6,5.640000000000001,6.68,7.720000000000001,8.76,9.8,10.84,11.88,12.920000000000002,13.96,{"y":15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.48,2.52,3.56,4.6,5.640000000000001,6.68,7.720000000000001,8.76,9.8,10.84,11.88,12.920000000000002,13.96,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.44,"date":1590969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1593561600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1596240000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1601510400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1604188800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1606780800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1619827200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >